U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H18F3N3O5
Molecular Weight 449.3799
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BICTEGRAVIR

SMILES

[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H]5CC[C@H](C5)O2

InChI

InChIKey=SOLUWJRYJLAZCX-LYOVBCGYSA-N
InChI=1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H18F3N3O5
Molecular Weight 449.3799
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:41:33 UTC 2023
Edited
by admin
on Sat Dec 16 08:41:33 UTC 2023
Record UNII
8GB79LOJ07
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BICTEGRAVIR
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
BICTEGRAVIR [MI]
Common Name English
bictegravir [INN]
Common Name English
BICTEGRAVIR [USAN]
Common Name English
GS-9883
Code English
GS-9883-01
Code English
Bictegravir [WHO-DD]
Common Name English
2,5-METHANOPYRIDO(1',2':4,5)PYRAZINO(2,1-B)(1,3)OXAZEPINE-10-CARBOXAMIDE, 2,3,4,5,7,9,13,13A-OCTAHYDRO-8-HYDROXY-7,9-DIOXO-N-((2,4,6-TRIFLUOROPHENYL)METHYL)-, (2R,5S,13AR)-
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 559316
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
WHO-ATC J05AR20
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID701027937
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
DAILYMED
8GB79LOJ07
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
NCI_THESAURUS
C171719
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
WIKIPEDIA
Bictegravir
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
MERCK INDEX
m12125
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
PUBCHEM
90311989
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
DRUG CENTRAL
5274
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
FDA UNII
8GB79LOJ07
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
CHEBI
172943
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
SMS_ID
100000169072
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
INN
10133
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
USAN
DE-56
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
EVMPD
SUB182699
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
RXCUI
1999660
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
CAS
1611493-60-7
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
DRUG BANK
DB11799
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
LACTMED
Bictegravir
Created by admin on Sat Dec 16 08:41:34 UTC 2023 , Edited by admin on Sat Dec 16 08:41:34 UTC 2023
PRIMARY
Related Record Type Details
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INTEGRASE
TARGET -> INHIBITOR
IC50
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Coadministration of BIC (given without F/TAF) with rifampin decreased the mean BIC Cmax and AUC by 28% and 75%, respectively.
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INTEGRASE
TARGET -> INHIBITOR
INHIBITOR
IC50
OCT-2
TRANSPORTER -> INHIBITOR
Co‐administration of BIKTARVY with dofetilide may increase dofetilide plasma concentrations which can lead to serious and/or life threatening events.
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> SUBSTRATE
Structure of BICTEGRAVIR SODIUM
SALT/SOLVATE -> PARENT
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
Co‐administration of BIKTARVY with dofetilide may increase dofetilide plasma concentrations which can lead to serious and/or life threatening events.
CLINICALLY SIGNIFICANT
IC50
Related Record Type Details
Structure of META-HYDROXY-BICTEGRAVIR
METABOLITE -> PARENT
Structure of META-SULFOOXY-BICTEGRAVIR
METABOLITE -> PARENT
PLASMA; URINE
Structure of BICTEGRAVIR GLUCURONIDE
METABOLITE -> PARENT
PLASMA
Related Record Type Details
Structure of BICTEGRAVIR
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Cmax PHARMACOKINETIC ROUTE OF ADMINSTRATION
PHARMACOKINETIC
DOSE
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966